Clinical experience with recombinant factor VIIa
作者:
J. Lusher,
J. Ingerslev,
H. Roberts,
U. Hedner,
期刊:
Blood Coagulation and Fibrinolysis
(OVID Available online 1998)
卷期:
Volume 9,
issue 2
页码: 119-128
ISSN:0957-5235
年代: 1998
出版商: OVID
关键词: recombinant factor VIIa;haemophilia;inhibitors
数据来源: OVID
摘要:
Recombinant factor VIIa (rFVIIa) represents a major therapeutic advance in the treatment of haemophilia patients with inhibitors. The efficacy and safety of rFVIIa has been extensively studied in over 1900 surgical and non-surgical bleeding episodes in over 400 patients with haemophilia A or B (with or without inhibitors) or acquired haemophilia. Of 103 evaluable surgical bleeding episodes, the response to treatment with rFVIIa was considered to be either excellent or effective in 81%, 86% and 92% of major, minor and dental bleeding episodes, respectively. Treatment has been evaluated in 518 serious bleeding episodes and the response was considered either excellent or effective in 62% of muscle, 80% of ear, nose and throat, 88% of central nervous system, 76% of joint, and 75% of internal or retroperitoneal bleeding episodes. An excellent safety profile has also been demonstrated: of 1957 treatments with rFVIIa, only 16 serious adverse events have been reported that were considered to be possibly, but not necessarily, related to treatment. Blood Coag Fibrinol 9:119–128 × 1998 Lippincott-Raven Publishers.
点击下载:
PDF
(888KB)
返 回